Contemporary pharmacological treatment strategies for patients with angina and unobstructed coronary arteries (ANOCA) due to coronary microvascular dysfunction

Johanna McChord, Astrid Hubert, Raffi Bekeredjian, Peter Ong

Department of Cardiology and Angiology, Robert-Bosch-Krankenhaus, Stuttgart 70376, Germany.

Correspondence to: Dr. Peter Ong, Department of Cardiology and Angiology, Robert-Bosch-Krankenhaus, Auerbachstr. 110, Stuttgart 70376, Germany. E-mail: peter.ong@rbk.de

How to cite this article: McChord J, Hubert A, Bekeredjian R, Ong P. Contemporary pharmacological treatment strategies for patients with angina and unobstructed coronary arteries (ANOCA) due to coronary microvascular dysfunction. Vessel Plus 2021;5:49. https://dx.doi.org/10.20517/2574-1209.2021.63

Received: 12 Apr 2021 First Decision: 11 Jun 2021 Revised: 18 Jun 2021 Accepted: 28 Jun 2021 First online: 5 Jul 2021

Abstract

In recent years, there has been important progress in the evolving field of coronary vasomotor disorders regarding diagnostic assessments and therapeutic strategies. It is now commonly accepted that patients with angina and unobstructed coronary arteries (ANOCA) frequently suffer from coronary vasomotor disorders. The latter can be reliably diagnosed using invasive diagnostic procedures. They comprise the detection of epicardial and/or microvascular spasm, impaired coronary vasodilatation, and enhanced microvascular resistance. As these mechanisms may overlap in one given patient, various endotypes of disease can be distinguished. Although evidence from randomized clinical trials in this setting is still sparse, it has been suggested that - in addition to strict risk factor control-targeted pharmacological therapies/treatments based on the identified mechanism of disease can improve symptoms and prognosis. In patients with coronary spasm as the predominant mechanism, first-line treatment consists of high-dose calcium channel blockers and nitrates. In patients with impaired vasodilatation or enhanced microvascular resistance, beta-blockers, angiotensin-converting enzyme inhibitors, and statins represent first-line treatment. In the group of patients with symptoms refractory to first-line medication, second-line drugs such as nicorandil, molsidomine, ranolazine, ivabradine, and others for microvascular dysfunction are available. Moreover, ongoing studies in this area are evaluating the usefulness of newer pharmacological agents such as endothelin-receptor antagonists or soluble guanylate cyclase stimulators. This article summarizes the currently available evidence for pharmacological treatment strategies in patients with
ANOCA due to coronary microvascular dysfunction.

**Keywords:** Angina with unobstructed coronary arteries, coronary microvascular dysfunction, coronary spasm, vasodilatation

**INTRODUCTION**

Coronary microvascular dysfunction (CMD) is still an under-recognized cardiac condition that can be responsible for the impairment of myocardial perfusion and ischemia\(^1\),\(^2\). In patients who show symptoms of coronary artery disease (CAD), CMD has a high prevalence, especially in women (54%)\(^3\). It is associated with adverse outcomes\(^4\)\(^-\)\(^9\), but currently there are no therapy guidelines available because large-scale evidence-based data are missing. In 2020, an EAPCI Expert Consensus Document on ischemia with non-obstructive coronary arteries endorsed by the “Coronary Vasomotor Disorders International Study Group” (COVADIS) was published which lists therapy recommendations\(^10\). Nevertheless, treatment tactics often remain empiric and should be adapted to the underlying pathomechanism as much as possible. Given the large number of patients affected by this condition, randomized studies for the evaluation of optimal treatment strategies are needed. This review focuses on pharmacotherapy in patients with angina and unobstructed coronary arteries (ANOCA) due to CMD.

**Definition of CMD**

Coronary microvessels with a diameter < 500 μm represent prearterioles and arterioles, which are characterized by a very large drop in pressure along their length. Arterioles are the spot of metabolic regulation of myocardial blood flow since their tone is altered by substances produced during myocardial metabolism\(^11\). CMD is defined as a mismatch of myocardial blood supply and oxygen consumption due to a dysregulation of coronary microvessels\(^1\). Both structural and functional changes in the microvasculature are possible causes. Vascular remodeling and rarefaction, perivascular fibrosis, and endothelial and vascular smooth muscle cell dysfunction have been described in CMD. The current classification of CMD contains four types: Type 1 is CMD in the absence of CAD and myocardial diseases; Type 2 is CMD in the presence of myocardial diseases; Type 3 is CMD in the presence of obstructive CAD; and Type 4 is iatrogenically induced CMD\(^1\).

**CMD in the absence of myocardial diseases and obstructive coronary artery disease**

In Type 1 CMD, several disturbances have been defined that may account for the clinical presentation of angina. They comprise coronary microvascular spasm\(^12\) and impaired coronary microvascular dilatation\(^13\) /enhanced microvascular resistance. Initially, Type 1 CMD was regarded as the functional equivalent of traditional coronary risk factors (smoking, hypertension, hyperlipidemia, and diabetes). However, the results of the “Women’s Ischemia Syndrome Evaluation” showed that traditional cardiovascular risk factors account for less than 20% of the observed variability in coronary flow reserve in response to adenosine\(^14\). Therefore, other mechanisms seem to be involved, and Type 1 CMD is only partly reversible by reducing the burden of common cardiovascular risk factors.

**Interventional diagnostic procedure**

Patients with CMD often present with angina or dyspnea suggestive for obstructive epicardial CAD, and many of them undergo invasive coronary angiography. However, the rate of obstructive CAD in this population is under 40%\(^15\). Therefore, the remaining ANOCA patients have a high probability to suffer from myocardial ischemia instigated by coronary vasomotor disorders including CMD\(^15\),\(^16\),\(^17\). To expedite an immediate diagnosis in these patients, invasive methods to evaluate the coronary microcirculation during coronary angiography are of great significance. For this purpose, several methods have been established
during the last decades. One of these methods, called interventional diagnostic procedure (IDP), includes coronary flow reserve (CFR) and coronary microvascular resistance (MVR) measurements by intracoronary Doppler or thermodilution and acetylcholine spasm provocation testing\cite{18}. IDP allows the evaluation of decreased vasodilation of the microvasculature in reaction to adenosine. In addition, it can also show an increased microvascular hyperconstrictive reaction to acetylcholine. The primary pathophysiology of CMD includes a pathological reaction of the coronary microvessels to structural, metabolic, and neurohumoral vasoactive provocations resulting in compromised vasodilatory capacity and/or enhanced microvascular vasoconstriction. Therefore, complete invasive assessments of coronary microvascular function contain the evaluation of the vasodilator as well as the vasoconstrictor microvascular responses.

Assessment of the vasoconstrictor element is confined to invasive methods\cite{19}. The standardized criteria for microvascular spasm focus on the patient’s reproduction of symptoms and ischemic electrocardiogram (ECG) alterations in the absence of epicardial spasm (< 90%) during the provocation test because there is currently no imaging technique available to illustrate the coronary microvascular function \textit{in vivo}\cite{20}.

CFR and/or MVR are usually measured as a ratio at rest and during hyperemia induced by adenosine, regadenoson, or dipyridamole. Those agents can be administered intravenously or intracoronary\cite{21,22}. Myocardial oxygen demand and coronary blood flow show an almost linear relationship. Hence, healthy subjects have a CFR up to 5\cite{23}. CFR may be decreased in patients with CMD but also in patients with an epicardial stenosis. Therefore, CFR can only be regarded as a measure of microvascular function in patients with unobstructed coronary arteries as it does not discriminate microvascular and epicardial disease. CFR has been demonstrated to rely on the patient’s hemodynamics at rest\cite{24}. That is why it was criticized for being dependent on baseline coronary flow\cite{25}. Due to these disadvantages of CFR, parameters autonomous of baseline coronary flow have been established. Those techniques measure the minimal MVR during maximal hyperemia. For this reason, Doppler and thermodilution wires designed with a supplementary distal pressure sensor are offered. They enable real-time measurements of the distal arterial pressure (Pd) and coronary flow or transit time. Contrary to CFR, MVR can measure microvascular function in the case of epicardial stenosis.

\textbf{Definition of endotypes}

In the context of IDP, different endotypes of vasomotion disorders can be distinguished, which are demonstrated in Figure 1. First, pathological vasodilation and pathological vasoconstriction can be differentiated. The endotype pathological vasoconstriction can then be further subdivided into epicardial vs. microvascular. The endotype pathological vasodilation, on the other hand, can be subdivided into pathological CFR vs. pathological resistance. The following statements attempt to highlight a targeted pharmacological therapy for ANOCA patients (Type 1 CMD) that differentiates according to the endotypes identified in IDP. Those patients show no macroscopic anatomical pathologies (absence of myocardial diseases and obstructive coronary artery diseases). However, structural, anatomic changes may still be present in the microvasculature (e.g., vascular remodeling and rarefaction and perivascular fibrosis). Since IDP also captures these microvascular changes by measuring MVR, the targeted treatment approach based on the IDP results is able to address both structural/anatomical and functional abnormalities.

\textbf{TARGETED PHARMACOLOGICAL THERAPIES}

The CORonary MIcrovascular Angina (CorMicA) trial\cite{18} randomized 151 patients with non-obstructive coronary disease to a stratified medical therapy group guided by the results of intracoronary testing vs. a control group receiving standard care. The results show a significant reduction of anginal symptoms in the tailored therapy group. Before offering tailored pharmacotherapy to ANOCA patients, the cardiovascular
risk profile of the patient should be evaluated. Studies have shown that common cardiovascular risk factors also affect the coronary microvasculature\(^26\). Therefore, a reduction of risk factors may also be beneficial for this patient population.

**Predominant mechanism: coronary spasms**

*Calcium channel blockers*

Calcium channel blockers (CCBs) prevent the voltage-dependent L-type calcium channel activation, and consequently they are smooth muscle dilators and negative inotropic and chronotropic substances. Several studies have stated the usefulness of CCBs in decreasing angina frequency in patients with epicardial vasospasms\(^{27,28}\). Treatment of microvascular spasms is less well established. CCBs are reportedly of limited efficacy in patients with microvascular angina\(^{29,30}\). Conversely, other studies have shown favorable effects of nisoldipine and diltiazem, indicating that at least a subset of patients with microvascular vasospastic angina benefits from CCB treatment\(^{29}\). Hence, CCBs are endorsed and are often effective in patients with CMD. A protective effect of CCBs is also supported in animal studies. For instance, amlodipine prevents inward remodeling in porcine coronary microvessels\(^{31}\). If patients report frequent attacks of angina pectoris and IDP reveals microvascular spasms (i.e., reproduction of angina during ACh provocation test without epicardial spasm but with ischemic ECG changes), a CCB treatment should be initiated as in the case of epicardial vasospasms. In addition, short acting nitrates are suggested to relieve spontaneous attacks of angina. However, patients often report a limited effect of these drugs. In these cases, sublingual nitrendipine
for a quick relief of symptoms is recommended.

Benidipine is a potent and long-acting CCB, which inhibits not only the L- and N- but also the T-type calcium channel and controls the vasoconstriction and vasodilation of renal efferent arterioles\textsuperscript{[32]}. It also inhibits aldosterone production\textsuperscript{[33,34]}, directly inhibits aldosterone-induced mineralocorticoid receptor activation\textsuperscript{[35,36]}, and has a sodium diuretic effect\textsuperscript{[37]}. Benidipine was initially licensed for use in Japan and selected Southeast Asian countries and later in Turkey. A meta-analysis that compared the prognostic effects of four CCBs (amlodipine, nifedipine, diltiazem, and benidipine) showed a significant superiority of benidipine regarding the occurrence of major adverse cardiovascular events in Japanese patients with a history of vasospastic angina attacks\textsuperscript{[38]}. In addition, use of benidipine showed significantly better control of angina symptoms compared with diltiazem\textsuperscript{[39]}. Benidipine improves endothelial dysfunction beyond blood pressure control in patients with coronary vasospasm. Upregulation of the nitric oxide (NO) cGMP system by benidipine may somewhat add to the improvement\textsuperscript{[40]}. Overall, the dihydropyridine (DHP) class may be more beneficial for vascular endothelial function than the non-dihydropyridine (non-DHP) classes of CCBs. However, since DHP CCBs can lead to reflex tachycardia, we usually use them in patients with a resting heart rate below 70 bpm. Patients with a resting heart rate above 70 bpm should be treated with a non-DHP CCB.

\textbf{Nitrates}

Besides CCBs, nitrates are commonly used as concomitant drugs for the treatment of epicardial vasospastic angina. Multiple studies have reported inconclusive results regarding the effectiveness of short-acting nitrates on angina pectoris symptoms in patients with CMD\textsuperscript{[41,42]}. It has been assumed that nitrates have different effects in the epicardial coronary arteries compared to the microvascular coronary arteries due to different signaling pathways\textsuperscript{[43]}. Studies on long-acting nitrates have usually shown no helpful effect, and they are therefore not suggested as first-line drugs in these patients\textsuperscript{[44]}. However, long-term consumption of nicorandil is not associated with poor clinical outcomes, in contrast to conventional nitrates\textsuperscript{[44]}. Nicorandil has a nitrate-like influence, releasing NO and causing vasodilation via cGMP signaling pathways\textsuperscript{[45,46]}. However, it also acts on $K_{ATP}$ channels of vascular smooth muscle cells and causes dilation of coronary microvessels and peripheral resistance arteries\textsuperscript{[47,48]}. Unlike conventional nitrates, nicorandil is not linked to tolerance or rebound angina, perhaps due to its two separate mechanisms of action\textsuperscript{[47,49]}. Furthermore, there is some indication that long-term use of nicorandil improves endothelial function alongside decreases in biomarkers of oxidative stress and systemic inflammation\textsuperscript{[50]}.

In our experiences, short-acting nitrates such as sublingual nitroglycerin spray are frequently effective in relieving chest pain symptoms in patients with vasospastic angina, particularly when given in addition to a CCB treatment. However, except for nicorandil, long-acting nitrates in the form of tablets are less effective at relieving symptoms in vasospastic angina patients.

\textbf{Predominant mechanism: impaired vasodilation/enhanced microvascular resistance}

\textbf{Beta-blockers}

In patients who show impaired vasodilation and enhanced microvascular resistance during IDP, the underlying pathophysiology is assumed to be based on microvascular remodeling (e.g., arteriolar narrowing, inward remodeling, or capillary rarefaction)\textsuperscript{[50]}. A principal goal of pharmacotherapy for the coronary microcirculation is a “normalization” of transformed microvascular structure (“re-remodeling”). Conventional beta-blockers appear to have an inadequate effect on re-remodeling. However, they act by blocking catecholamine-induced increase in heart rate, blood pressure, and myocardial contractility, thereby reducing myocardial oxygen demand and consumption\textsuperscript{[50]}. This is reflected in a reduced resting coronary
flow causing an increase in coronary blood flow reserve\textsuperscript{53}. A class of beta-blockers that releases NO seems especially beneficial in cases of a predominant vasodilation impairment with additional coronary spasms diagnosed during acetylcholine provocation testing\textsuperscript{54,55}.

**Angiotensin-converting enzyme inhibitors/Angiotensin II receptor blockers**

Endothelium-dependent vasodilation can at least partly be restored by several medications. These include angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II receptor blockers (ARB)\textsuperscript{56-58}. ACE-I and ARB decrease production of angiotensin II, which has vasoconstrictive properties. They also decrease degradation of endothelial bradykinin, which stimulates production of NO and other vasodilators. ACE-I and ARB can therefore improve coronary microvascular function as assessed by CFR and/or MVR. In a small randomized, placebo controlled study by Pauly \textit{et al.}\textsuperscript{59}, patients with CMD and reduced CFR took quinapril or placebo for 16 weeks. The ACE-I group showed significant increase in CFR, which was linked to reduced angina frequency. In a systematic review of interventional studies regarding treatment strategies in CMD\textsuperscript{60}, the authors concluded that several small studies ($n = 12$-78) show a positive treatment effect of ACE-I/ARBs on coronary microvascular function. The studies suggest that the treatment effect is more pronounced in patients with a considerable CFR-reduction. However, the evidence backing up the usage of ACE-I/ARBs to treat CMD is sparse and larger, well-designed, placebo-controlled studies are needed.

**Statins**

Statins can reduce low-density lipoprotein (LDL) levels and subsequently cardiovascular risk. In addition, they probably improve coronary (micro-)circulation due to their lasting structural and functional effects on arteries. Those effects appear to be autonomous from their LDL dropping impact\textsuperscript{61}. They are most likely due to statins being involved in the inhibition of Rho/Rho-kinase, which in turn blocks the expression and activity of endothelial NO synthase. Therefore, statins increase the bioavailability of NO\textsuperscript{62}. Furthermore, they reduce oxidative stress and inflammation. All those effects are advantageous to uphold and increase coronary (micro-)circulation. A small randomized study by Zhang \textit{et al.}\textsuperscript{63} found significant improvement in CFR after treatment with a combination of fluvastatin and diltiazem compared with fluvastatin or diltiazem alone in patients with angina pectoris and normal epicardial arteries on angiogram. Another randomized study by Yokoyama \textit{et al.}\textsuperscript{64} described significant improvement from baseline CFR after treatment with simvastatin but not pravastatin in patients with high cholesterol and a low likelihood of CAD. Based on these studies, the use of statins is recommended for most patients with CMD but especially for the endotype of impaired vasodilation unless severe side effects or contraindications are present.

**Second-line treatments for patients with refractory symptoms**

Patients should be followed up every 3-6 months in an outpatient clinic where the effect of the pharmacotherapy is assessed. In our experience, for 30%-40% of patients with ANOCA, symptoms will not have improved. In this case, the first step is to increase the dosage of the drugs used to the maximum tolerated dosage. If this approach does not help, additional antianginal drugs should be given.

**Nicorandil**

As stated above, nicorandil has a nitrate-like influence, releasing NO and causing vasodilation via cGMP signaling pathways\textsuperscript{45,46}. The effect of nicorandil in patients with ANOCA was recently summarized by Jia \textit{et al.}\textsuperscript{65} in a meta-analysis of 24 randomized controlled trials. The main outcomes were improvement of angina symptoms and resting ECG and prolongation until a 1 mm ST-segment depression on a treadmill test occurred. Furthermore, nicorandil reduced the level of endothelin-1 (ET-1) and increased the level of NO. Although nicorandil is presently not approved for sale in Germany or the United States of America, it can be acquired through international pharmacies for treatment of CMD patients with refractory
symptoms. In these patients, we repeatedly found it to be useful in improving angina symptoms.

**Molsidomine**

The NO donor molsidomine releases NO non-enzymatically, avoiding tolerance. Bassenge *et al.* reported in 1985 about the vascular and hemodynamic effects of molsidomine in chronically instrumented dogs: molsidomine causes a significant dilatation of epicardial coronary arteries and the peripheral venous system, whereas coronary resistance vessels (arterioles) are not affected. Because of the combined effects of reduced cardiac preload and increased epicardial blood flow, the myocardial oxygen supply and the supply/demand ratio is improved. In countries where molsidomine is available, it can be used in the nitrate-free interval to suppress coronary spasm.

**Ranolazine**

Ranolazine has an exceptional mechanism of action that does not disturb blood pressure or heart rate. It inhibits the late phase of the inward sarcolemmal sodium channel and thereby prevents intracellular calcium overload in cardiac myocytes. Calcium overload can cause or aggravate diastolic dysfunction due to increased myofilament stimulation. Amplified diastolic tone increases microcirculatory resistance and further harms the energy balance of the ischemic myocardium. Overall, ranolazine reduces ischemia and angina symptoms and improves diastolic function by reducing diastolic tension without affecting contractility and improving coronary blood flow. The drug was approved in a sustained release formulation for use in chronic stable angina. A recent review by Sharp *et al.* scanned the data for the use of ranolazine in pharmacologic management of CMD. Eight of ten studies indicated that ranolazine improved at least one aspect of patient health status as assessed by questionnaires when added to existing anti-anginal drugs. Five studies evaluated CFR and showed that patients with low values had significant increases in CFR when using ranolazine. This might mean that those patients with severe CMD respond better to ranolazine. In two studies, exercise duration and time to myocardial ischemia (indicated by time to 1 mm ST-segment depression on the exercise stress ECG) were significantly longer after treatment with ranolazine. Nevertheless, larger and longer studies are needed to fully evaluate the effectiveness of ranolazine in CMD.

**Ivabradine**

Ivabradine is a specific heart rate lowering drug that acts in sinoatrial node cells by selectively inhibiting a mixed Na⁺-K⁺ inward current without the common side effects of beta-blockers. It has revealed anti-ischemic and anti-anginal effects in a placebo-controlled study comprising 360 patients with stable angina. A prospective, randomized, placebo-controlled, parallel study by Villano *et al.* evaluated the effects of ivabradine and ranolazine in 46 microvascular angina patients who had symptoms ineffectively controlled by standard anti-anginal treatment. Both agents improved items on the Seattle Angina Questionnaire and the EuroQoL scale compared with placebo. Ranolazine showed a slightly more significant effect than ivabradine. The authors assessed the coronary microvascular dilator response to adenosine and cold pressor test by transthoracic echo-color-Doppler. However, coronary microvascular function and flow-mediated dilation did not improve. This indicates that symptom recovery could be ascribed to the effect of a slower heart rate alone. Contrary, other research groups have reported that ivabradine increases CFR in patients with stable CAD and non-obstructed coronary arteries. These improvements even persisted after heart rate correction, which hints towards better microvascular function.
**Xanthine derivatives**

Adenosine can be a mediator for angina. It is released from the ischemic myocardium and likely contributes to an enhanced chest pain perception. Xanthine derivatives can block adenosine receptors and therefore reach an antianginal effect\[^{77,78}\]. In addition, they show an anti-ischemic influence by reallocating coronary blood flow towards ischemic parts of the myocardium\[^{79}\].

**Tricyclic antidepressants**

In patients with refractory angina and heightened pain sensitivity, drugs for the treatment of chronic pain syndromes such as tricyclic antidepressants may be beneficial\[^{80}\]. The effect of pain reduction due to antidepressants is not entirely understood. They can induce an upsurge of neurotransmitters that weaken pain perception. The maximal benefit is reached after a number of weeks, but patients may notice some relief after 7-10 days. Tricyclics are the most widely used antidepressants for pain regulation\[^{81}\].

**Spinal cord stimulation and enhanced external counter pulsation**

If the pharmacological treatment strategies have come to a limit, e.g., because of contraindications, side effects, drug interactions, or patients’ compliance, spinal cord stimulation (SCS) or enhanced external counter pulsation (EECP) may be considered. Especially SCS has been proven to reduce angina, decrease the occurrence of hospital admissions, and improve patients’ quality of life\[^{82,83}\]. It has been used as a treatment option in patients with obstructive CAD and refractory angina symptoms who were not suited for revascularization\[^{84}\]. In addition, there are studies pointing out that SCS can help in short- and long-term control of angina episodes in ANOCA patients as well\[^{83,85}\]. The data regarding the effectiveness of EECP in ANOCA patients are less robust, but it has been proven to ease chest pain and improve quality of life in patients with obstructive CAD\[^{86,87}\].

**OUTLOOK ON NEWER DRUGS**

**Endothelin-receptor antagonists**

ET-1 contributes to coronary endothelial dysfunction\[^{88}\]. It has an inhibitory influence on the perfusion of the myocardium and is linked to patients’ risk factors for atherosclerosis\[^{89}\]. In patients with microvascular angina, ET-1 is increased and associated with faster occurrence of angina during exercise\[^{90}\]. Moreover, some authors have proposed augmented ET-1 activity being connected to reduced CFR in women\[^{91}\]. Johnson et al.\[^{92}\] showed that an irregular cluster of diffuse myocardial perfusion was linked to ET-1 activity in CMD patients. The endothelin-receptor-antagonist (ERA) darusentan increased myocardial perfusion and enhanced perfusion’s regularity. These results indicate that ET-1 causes local declines in myocardial perfusion in patients with CMD. This effect can be inhibited by ERAs. In a randomized, placebo-controlled study using the ERA atrasentar for 6 months in patients with CMD, microvascular coronary endothelial function could be improved\[^{93}\]. The CorMicA investigators revealed that peripheral arterioles from patients with ANOCA showed a stronger constriction to ET-1 in comparison to controls\[^{94}\]. These discoveries sustain the theory that patients with ANOCA are more likely to develop systemic small vessel dysfunction/disease. Currently, the “Precision Medicine with Zibotentan in Microvascular Angina (PRIZE)” study is enrolling 356 patients in multiple centers across the UK. This placebo-controlled, crossover design investigates the ERA zibotentan in patients with microvascular angina in terms of exercise duration without angina. A cMRI substudy might deliver insights about the impacts on myocardial blood flow.

**Soluble guanylate cyclase stimulators**

The soluble guanylate cyclase (sGC) derives cyclic guanosine monophosphate (cGMP). Deficiency in cGMP causes myocardial dysfunction and impaired endothelium-dependent vasomotor regulation including the microcirculation\[^{95}\]. Vericiguat, a sGC-stimulator investigated in the VICTORIA trial, has been shown to
directly stimulate sGC as well as increase sGC sensitivity to endogenous NO and thus enhance the cGMP pathway\textsuperscript{[96]}. This selectivity in cGMP generation does not occur with nitrates or phosphodiesterase inhibitors. Vericiguat is optimized for patients with chronic heart failure. Beyond its vasodilatory properties, low-dose sGC stimulation in preclinical models has been shown to also have direct antifibrotic effects, improving myocardial remodeling and diastolic relaxation in the absence of any hemodynamic effects. Our research group recently reported about a clinical case\textsuperscript{[97]} of a 77-year-old woman with refractory angina despite conventional anti-anginal treatment. During ACh provocation testing, microvascular and epicardial coronary spasms could be observed. Given that the diagnosis of a coronary vasomotor disorder was then established and recommended pharmacological therapy opportunities to achieve satisfactory symptom control were exhausted, we tried an off-label use of riociguat. Riociguat, approved for the treatment of pulmonary hypertension, is another sGC-stimulator. We increased the dosage during weekly follow-ups until the patient reported significant decrease of angina and dyspnea symptoms. Finally, she reported to be almost symptom-free with a significant improvement in quality of life. Plasma levels of riociguat and its metabolite were analyzed showing a dose-dependent increase of plasma concentrations. Moreover, the patient underwent repeated ACh provocation testing to confirm the anti-vasospastic effect of riociguat on the coronary arteries. Under full riociguat medication, epicardial coronary artery spasm could not be provoked, unlike in an earlier examination with “classical” anti-vasospastic medication.
CONCLUSION

CMD is a significant clinical condition in ANOCA that should be recognized since patients often endure symptoms leading to repetitive emergency room visits and numerous further examinations. Moreover, CMD has been shown to be prognostically relevant\[^{1,3}\]. Prospective, randomized, placebo-controlled trials in well-characterized sub-cohorts (identified by an interventional diagnostic procedure) are necessary to categorize the best pharmacological treatment. Only then can guidelines be established to help physicians in the management of these patients and eventually improve their prognosis. Currently, we recommend strict control of cardiovascular risk factors; anti-anginal medication with CCBs and nitrates in patients with coronary spasm as the predominant mechanism; and beta-blockers, ACE-inhibitors, and statins in patients with reduced vasodilatation or enhanced microvascular resistance. In patients with symptoms refractory to first-line medication, second-line drugs such as nicorandil, molsidomine, ranolazine, or ivabradine are available. Moreover, ongoing studies are evaluating the usefulness of newer pharmacological agents such as endothelin-receptor antagonists or soluble guanylate cyclase stimulators. Figure 2 illustrates different pharmacological treatment algorithms based on the underlying vasomotion disorder.

DECLARATIONS

Authors’ contributions
Performed the literature search, data analysis and she produced the first draft of the manuscript: McChord J
Had the idea for the article and the topic and made critical revisions of the manuscript: Ong P
Performed literature search and made critical revisions: Hubert A
Made suggestions for the scope of the article and made critical revisions: Bekeredjian R

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by funds from the Berthold-Leibinger-Foundation, Ditzingen, Germany.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2021.

REFERENCES

5. Huang FY, Huang BT, Lv WY, et al. The prognosis of patients with nonobstructive coronary artery disease versus normal arteries determined by invasive coronary angiography or computed tomography coronary angiography: a systematic review. *Medicine*
Sorop O, Bakker EN, Pistea A, Spaan JA, VanBavel E. Calcium channel blockade prevents pressure-dependent inward remodeling in microvascular spasm.

Masumoto A, Mohri M, Takeshita A. Three-year follow-up of the Japanese patients with microvascular angina attributable to coronary syndrome X.

Lanza GA, Colonna G, Pasceri V, Maseri A. Atenolol versus amlodipine versus isosorbide-5-mononitrate on anginal symptoms in humans. Feasibility, reproducibility, and hemodynamic dependence of coronary flow velocity reserve, hyperemic flow versus pressure slope index, and fractional flow reserve.


34. Tani S, Takahashi A, Nagao K, Hirayama A. Effects of the T/L-type calcium channel blocker benidipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benidipine. *Int Heart J* 2014;55:519-25. DOI PubMed


61. Lefer A. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for


90. Cox ID, Borker HE, Bagger JP, Sonne HS, Kristensen BØ, Kaski JC. Elevated endothelin concentrations are associated with reduced...
coronary vasomotor responses in patients with chest pain and normal coronary arteriograms. *J Am Coll Cardiol* 1999;34:455-60. DOI


